Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA

CARMIEL, Israel and BOSTON, April 28, 2021 -- (Healthcare Sales & Marketing Network) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant ... Biopharmaceuticals, FDA Protalix BioTherapeutics, Chiesi , Fabry disease, pegunigalsidase alfa
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news